The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
[EN] TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROTHIÉNO PYRIDINE EN TANT QU'INHIBITEURS DE DDR
申请人:CHIESI FARM SPA
公开号:WO2022200580A1
公开(公告)日:2022-09-29
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).